Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Nephron Exp Nephrol ; 111(1): e20-30, 2009.
Artigo em Inglês | MEDLINE | ID: mdl-19052474

RESUMO

BACKGROUNDS/AIMS: It has been reported that urinary oxidative stress markers are higher in diabetic patients with proteinuria. We performed the present study to elucidate the relationship between urinary excretion of oxidative stress markers, albumin excretion, and histological changes, and to confirm the potential utility of oxidative stress markers for clinical treatment. METHODS: Diabetic db/db mice or nondiabetic db/m mice were administered candesartan (10 mg/kg/day) or hydralazine (50 mg/kg/day) for 18 weeks. RESULTS: Thirty-week-old male db/db mice treated with control vehicle revealed elevated urinary excretion and immunohistological levels of 8-hydroxydeoxyguanosine in glomeruli when compared to db/m mice. Treatment with candesartan, but not hydralazine, reduced these values to levels in db/m mice. Increased mesangial expansion, urinary excretion of albumin and 8-isoprostane, and glomerular immunohistological levels of nitrotyrosine in db/db mice were also decreased markedly by candesartan but not hydralazine. Interestingly, correlations between levels of albumin and oxidative stress markers in urine were very high, even when groups undergoing long-term (44 weeks) treatment were included (correlation coefficient 0.767 with respect to 8-hydroxydeoxyguanosine, 0.888 with respect to 8-isoprostane). CONCLUSION: It is anticipated that urinary concentrations of oxidative stress markers will be direct barometers of glomerulus-derived oxidative stress and glomerular injury in diabetic nephropathy.


Assuntos
Bloqueadores do Receptor Tipo 1 de Angiotensina II/uso terapêutico , Benzimidazóis/uso terapêutico , Desoxiguanosina/análogos & derivados , Nefropatias Diabéticas/tratamento farmacológico , Nefropatias Diabéticas/urina , Dinoprosta/análogos & derivados , Tetrazóis/uso terapêutico , Tirosina/análogos & derivados , 8-Hidroxi-2'-Desoxiguanosina , Albuminúria/urina , Bloqueadores do Receptor Tipo 1 de Angiotensina II/farmacocinética , Animais , Anti-Hipertensivos/uso terapêutico , Benzimidazóis/farmacocinética , Biomarcadores/urina , Compostos de Bifenilo , Desoxiguanosina/urina , Diabetes Mellitus/fisiopatologia , Diabetes Mellitus/urina , Nefropatias Diabéticas/fisiopatologia , Dinoprosta/urina , Modelos Animais de Doenças , Hidralazina/uso terapêutico , Glomérulos Renais/metabolismo , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Estresse Oxidativo/fisiologia , Tetrazóis/farmacocinética , Resultado do Tratamento , Tirosina/urina
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...